Article(id=1322624442665128136, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1322624441868202943, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2026.09.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1754928000000, receivedDateStr=2025-08-12, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793267840305, onlineDateStr=2026-10-29, pubDate=1788969600000, pubDateStr=2026-09-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793267840305, onlineIssueDateStr=2026-10-29, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793267840305, creator=13701087609, updateTime=1793267840305, updator=13701087609, issue=Issue{id=1322624441868202943, tenantId=1146029695717560320, journalId=1319690259887390882, year='2026', volume='57', issue='9', pageStart='1023', pageEnd='1140', issueExtLink='null', onlineDate='null', pubDate='1788969600000', pubDateStr='2026-09-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=1, specialIssue=null, createTime=1793267840115, creator='13701087609', updateTime=1793872373377, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325160038419006181, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1322624441868202943, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325160038419006182, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1322624441868202943, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1030, endPage=1038, ext={EN=ArticleExt(id=1322624444443513034, articleId=1322624442665128136, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Detection Methods for the Drug-antibody Ratio in Antibody-drug Conjugates and Design Strategies for Homogeneity, columnId=1322624444355432649, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspective & Review, runingTitle=null, highlight=null, articleAbstract=

The drug-to-antibody ratio(DAR) is a critical quality attribute of antibody-drug conjugates(ADCs),directly affecting their efficacy, safety, and pharmacokinetic properties. This review systematically summarizes the analytical methods for DAR determination and optimization strategies for homogeneous ADCs. Current detection technologies include hydrophobic interaction chromatography, reversed-phase high-performance liquid chromatography, mass spectrometry,ultraviolet-visible spectroscopy, and emerging multi-dimensional liquid chromatography hyphenated techniques. In terms of homogeneity optimization, engineered site-specific conjugation approaches(e.g., THIOMAB, enzymatic conjugation)enable precise control of DAR. Hydrophilic modification of linkers and optimization of payload structure help improve drug loading while maintaining antibody stability. The optimal DAR should be determined by comprehensively considering target expression levels, tumor heterogeneity, and payload properties. This review provides references for ADC process development and quality control.

, authors=Mengni FAN, Tingting ZHANG, Guohong QIN*, authorsList=Mengni FAN, Tingting ZHANG, Guohong QIN, authorCompany=null, correspAuthors=Guohong QIN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322624444808417484, articleId=1322624442665128136, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=抗体偶联药物中药物-抗体比的检测方法以及均一性的设计策略, columnId=1322624444544176331, journalTitle=中国医药工业杂志, columnName=专论与综述, runingTitle=null, highlight=null, articleAbstract=

药物-抗体比(DAR)是抗体偶联药物的核心质量属性,直接影响其疗效、安全性和药代动力学特性。文章系统总结了DAR的检测方法及均一性ADC的优化策略。现有检测技术包括疏水作用色谱、反相高效液相色谱、质谱法、紫外-可见光谱法及新兴的多维液相联用技术等。在均一性优化方面,工程化定点偶联(如THIOMAB、酶催化偶联等)可实现DAR的精确控制;连接子的亲水性修饰与有效载荷结构的优化,均有助于提高载药量并维持抗体稳定性。确定最佳DAR时,需综合考虑靶标表达、肿瘤异质性及有效载荷性质等因素。该文可为ADC的工艺开发与质量控制提供参考。

, authors=樊梦妮, 张婷婷, 秦国宏*, authorsList=樊梦妮, 张婷婷, 秦国宏, authorCompany=null, correspAuthors=秦国宏, authorNote=

樊梦妮,工程师,硕士,从事新药相关的质量研究。

, correspAuthorsNote=
秦国宏,副研究员,博士,从事新药研发工作。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=d2oZKLonhZ7zlO4BD6kKug==, magXml=19bnrBVdYI8rqsNgXaY/cw==, pdfUrl=null, pdf=mY0NuRpkXA7ARKFNsRtiHw==, pdfFileSize=1067594, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=jh/mga29CPEJ72NWxWyiUg==, mapNumber=null, fund=null)}, authors=[Author(id=1322624445152350417, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322624445236236499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445152350417, language=EN, stringName=Mengni FAN, firstName=Mengni, middleName=null, lastName=FAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445303345364, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445152350417, language=CN, stringName=樊梦妮, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio={"content":"

樊梦妮,工程师,硕士,从事新药相关的质量研究。

"}, bioImg=null, bioContent=

樊梦妮,工程师,硕士,从事新药相关的质量研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])]), Author(id=1322624445383037142, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322624445479506136, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445383037142, language=EN, stringName=Tingting ZHANG, firstName=Tingting, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445546615001, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445383037142, language=CN, stringName=张婷婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])]), Author(id=1322624445630501083, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322624445714387165, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445630501083, language=EN, stringName=Guohong QIN, firstName=Guohong, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445781496030, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445630501083, language=CN, stringName=秦国宏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])])], keywords=[Keyword(id=1322624445877965023, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=1, keyword=antibody-drug conjugate), Keyword(id=1322624445949268192, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=2, keyword=drug-to-antibody ratio), Keyword(id=1322624446037348577, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=3, keyword=antineoplastics), Keyword(id=1322624446125428962, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=4, keyword=detection method), Keyword(id=1322624446196732131, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=5, keyword=conjugation strategy), Keyword(id=1322624446268035300, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=6, keyword=homogeneity), Keyword(id=1322624446330949861, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=EN, orderNo=7, keyword=research progress), Keyword(id=1322624446402253030, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=1, keyword=抗体偶联药物), Keyword(id=1322624446481944807, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=2, keyword=药物-抗体比), Keyword(id=1322624446549053672, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=3, keyword=抗肿瘤药), Keyword(id=1322624446607773929, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=4, keyword=检测方法), Keyword(id=1322624446679077098, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=5, keyword=偶联策略), Keyword(id=1322624446750380267, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=6, keyword=均一性), Keyword(id=1322624446821683436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, language=CN, orderNo=7, keyword=研究进展)], refs=[Reference(id=1322624446926541037, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Ducry L, Stump B.Antibody—drug conjugates: LINking cytotoxic payloads to monoclonal antibodies [J].Bioconjug Chem, 2010, 21(1): 5-13., articleTitle=null, refAbstract=null), Reference(id=1322624447014621422, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Kvirkvelia N, Chikadze N, Makinde J, et al.Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine [J].Clin Exp Immunol, 2018, 193(1): 73-83., articleTitle=null, refAbstract=null), Reference(id=1322624447085924591, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Dan N, Setua S, Kashyap V K, et al.Antibody-drug conjugates for cancer therapy: chemistry to clinical implications [J].Pharmaceuticals, 2018, 11(2): 32., articleTitle=null, refAbstract=null), Reference(id=1322624448742674672, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=郭立红, 王金朋, 翟立海, 等.抗体偶联药物和小分子偶联药物的研究进展[J].中国医药工业杂志, 2019, 50(8):842-851., articleTitle=null, refAbstract=null), Reference(id=1322624448818172145, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Casi G, Neri D.Antibody-drug conjugates: basic concepts,examples and future perspectives [J].J Control Release,2012, 161(2): 422-428., articleTitle=null, refAbstract=null), Reference(id=1322624448876892402, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Sassoon I, Blanc V.Antibody-drug conjugate(ADC) clinical pipeline: a review [J].Methods Mol Biol, 2013, 1045: 1-27., articleTitle=null, refAbstract=null), Reference(id=1322624448939806963, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Ducry L.Antibody-drug conjugates [M].Berlin/Heidelberg: Springer Science, 2013., articleTitle=null, refAbstract=null), Reference(id=1322624449015304436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Hinrichs M J M, Dixit R.Antibody drug conjugates:nonclinical safety considerations [J].AAPS J, 2015, 17:1055-1064., articleTitle=null, refAbstract=null), Reference(id=1322624449074024693, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Hamilton G S.Antibody-drug conjugates for cancer therapy:the technological and regulatory challenges of developing drug-biologic hybrids [J].Biologicals, 2015, 43(5): 318-332., articleTitle=null, refAbstract=null), Reference(id=1322624449141133558, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Lambert J M.Antibody-drug conjugates(ADC): magic bullets at last! [J].Mol Pharm, 2015, 12(6): 1701-1702., articleTitle=null, refAbstract=null), Reference(id=1322624449204048119, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Diamantis N, Banerji U.Antibody-drug conjugates: an emerging class of cancer treatment [J].Br J Cancer, 2016,114: 362-367., articleTitle=null, refAbstract=null), Reference(id=1322624449258574072, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Mahmood I.Clinical pharmacology of antibody-drug conjugates [J].Antibodies, 2021, 10(2): 20., articleTitle=null, refAbstract=null), Reference(id=1322624449329877241, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Hussain A F, Grimm A, Sheng W J, et al.Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches [J].Pharmaceuticals, 2021, 14(4):343., articleTitle=null, refAbstract=null), Reference(id=1322624449388597498, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Guo J X, Kumar S, Chipley M, et al.Characterization and higher-order structure assessment of an interchain cysteine-based ADC: impact of drug loading and distribution on the mechanism of aggregation [J].Bioconjug Chem, 2016,27(3): 604-615., articleTitle=null, refAbstract=null), Reference(id=1322624449464094971, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Aoyama M, Tada M, Yokoo H, et al.Linker and conjugation site synergy in antibody-drug conjugates: impacts on biological activity [J].Bioconjug Chem, 2024, 35(10): 1568-1576., articleTitle=null, refAbstract=null), Reference(id=1322624449547981052, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Metrangolo V, Engelholm L H.Antibody-drug conjugates:the dynamic evolution from conventional to next-generation constructs [J].Cancers, 2024, 16(2): 447., articleTitle=null, refAbstract=null), Reference(id=1322624449606701309, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Matsuda Y, Leung M, Okuzumi T, et al.A purification strategy utilizing hydrophobic interaction chromatography to obtain homogeneous species from a site-specific antibody drug conjugate produced by AJICAP™ first generation [J].Antibodies, 2020, 9(2): 16., articleTitle=null, refAbstract=null), Reference(id=1322624449669615870, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Haverick M, Mengisen S, Shameem M, et al.Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications [J].mAbs, 2014, 6(4): 852-858., articleTitle=null, refAbstract=null), Reference(id=1322624449745113343, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Matsuda Y, Robles V, Malinao M C, et al.Comparison of analytical methods for antibody-drug conjugates produced by chemical site-specific conjugation: first-generation AJICAP[J].Anal Chem, 2019, 91(20): 12724-12732., articleTitle=null, refAbstract=null), Reference(id=1322624449803833600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Cordova J C, Sun S, Bos J, et al.Development of a single-step antibody-drug conjugate purification process with membrane chromatography [J].J Clin Med, 2021, 10(3):552., articleTitle=null, refAbstract=null), Reference(id=1322624449858359553, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=XU Y R, JISNG G F, TRAN C, et al.RP-HPLC DAR characterization of site-specific antibody drug conjugates produced in a cell-free expression system [J].Org Process Res Dev, 2016, 20(6): 1034-1043., articleTitle=null, refAbstract=null), Reference(id=1322624449917079810, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen T H, Yang Y, Zhang Z R, et al.Native reversed-phase liquid chromatography: a technique for LCMS of intact antibody-drug conjugates [J].Anal Chem, 2019, 91(4):2805-2812., articleTitle=null, refAbstract=null), Reference(id=1322624450000965891, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Srikanth K, David P, Sayumi Y, et al.Universal affinity capture liquid chromatography-mass spectrometry assay for evaluation of biotransformation of site-specific antibody drug conjugates in preclinical studies [J].Anal Chem, 2020,92(2): 2065-2073., articleTitle=null, refAbstract=null), Reference(id=1322624450089046276, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen L X, Wang L, Shion H, et al.In-depth structural characterization of Kadcyla®(ado-trastuzumab emtansine) and its biosimilar candidate [J].mAbs, 2016, 8(7): 1210-1223., articleTitle=null, refAbstract=null), Reference(id=1322624450147766533, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang T D, Huang Z A, Zhou M Y, et al.Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates [J].J Pharm Biomed Anal, 2024, 243:116098., articleTitle=null, refAbstract=null), Reference(id=1322624450223264006, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Källsten M, Hartmann R, Artemenko K, et al.Qualitative analysis of antibody-drug conjugates(ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCs[J].Analyst, 2018, 143(22): 5487-5496., articleTitle=null, refAbstract=null), Reference(id=1322624450281984263, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Jones J, Pack L, Hunter J H, et al.Native size-exclusion chromatography-mass spectrometry: suitability for antibody-drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels [J].mAbs,2019, 12(1): 1682895., articleTitle=null, refAbstract=null), Reference(id=1322624450344898824, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Leblanc Y, Faid V, Lauber M A, et al.A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry [J].J Chromatogr B,2019, 1133: 121814., articleTitle=null, refAbstract=null), Reference(id=1322624450403619081, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Matsuda Y, Kliman M, Mendeisohn B A.Application of native ion exchange mass spectrometry to intact and subunit analysis of site-specific antibody-drug conjugates produced by AJICAP first generation technology [J].J Am Soc Mass Spectrom, 2020, 31(8): 1706-1712., articleTitle=null, refAbstract=null), Reference(id=1322624450479116554, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Zong H F, Li X, Han L, et al.A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer [J].Acta Pharmacol Sin, 2024, 45(8): 1727-1739., articleTitle=null, refAbstract=null), Reference(id=1322624450550419723, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Andris S, Rüdt M, Rogalla J, et al.Monitoring of antibody-drug conjugation reactions with UV/Vis spectroscopy [J].J Biotechnol, 2018, 288: 15-22., articleTitle=null, refAbstract=null), Reference(id=1322624450617528588, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Botzanowski T, Erb S, Hernandez-Alba O, et al.Insights from native mass spectrometry approaches for top- and middle-level characterization of site-specific antibody-drug conjugates [J].mAbs, 2017, 9(5): 801-811., articleTitle=null, refAbstract=null), Reference(id=1322624450684637453, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Kempen T, Cadang L, Fan Y C, et al.Online native hydrophobic interaction chromatography-mass spectrometry of antibody-drug conjugates [J].mAbs, 2024, 17(1): 2446304., articleTitle=null, refAbstract=null), Reference(id=1322624450772717838, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Alicja M, Świderska K W, Otlewski J.Current methods for the synthesis of homogeneous antibody-drug conjugates [J].Biotechnol Adv, 2015, 33(6): 775-784., articleTitle=null, refAbstract=null), Reference(id=1322624450844021007, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Gao W L, Zhang J X, Xiang J, et al.Recent advances in site specific conjugations of antibody drug conjugates(ADC) [J].Curr Cancer Drug Targets, 2016, 16(6): 469-479., articleTitle=null, refAbstract=null), Reference(id=1322624450919518480, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun X X, Ponte J F, Yoder N C, et al.Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy,and tolerability of antibody-maytansinoid conjugates [J].Bioconjug Chem, 2017, 28(5): 1371-1381., articleTitle=null, refAbstract=null), Reference(id=1322624450995015953, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=D’Atri V, Peli R, Clarke A, et al.Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates? [J].J Chromatogr A,2019, 1586: 149-153., articleTitle=null, refAbstract=null), Reference(id=1322624451057930514, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Panowski S, Bhakta S, Raab H, et al.Site-specific antibody drug conjugates for cancer therapy [J].mAbs, 2014, 6(1):34-45., articleTitle=null, refAbstract=null), Reference(id=1322624451120845075, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Ou C, Li C, Zhang R S, et al.One-pot conversion of free sialoglycans to functionalized glycan oxazolines and efficient synthesis of homogeneous antibody-drug conjugates through site-specific chemoenzymatic glycan remodeling [J].Bioconjug Chem, 2021, 32(8): 1888-1897., articleTitle=null, refAbstract=null), Reference(id=1322624451183759636, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Farràs M, Miret J, Camps M, et al.Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly [J].mAbs,2020, 12(1): 1702262., articleTitle=null, refAbstract=null), Reference(id=1322624451250868501, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Dannheim F M, Stephen W, Orozco C T, et al.All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading [J].Chem Sci, 2022,13(30): 8781-8790., articleTitle=null, refAbstract=null), Reference(id=1322624451322171670, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang Z J, Li H X, Gou L T, et al.Antibody-drug conjugates:recent advances in payloads [J].Acta Pharm Sin B, 2023,13(10): 4025-4059., articleTitle=null, refAbstract=null), Reference(id=1322624451385086231, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Goldenberg D M, Cardillo T M, Govindan S V, et al.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan(IMMU-132), an antibody-drug conjugate(ADC)[J].Oncotarget, 2015, 6(26): 22496-22512., articleTitle=null, refAbstract=null), Reference(id=1322624451448000792, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=马骏威, 刘永辉, 任连杰.抗体偶联药物的小分子部分药学研究考虑 [J].中国医药工业杂志, 2025, 56(11): 1464-1470., articleTitle=null, refAbstract=null), Reference(id=1322624451510915353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Nadkarni D V, Lee J, Jiang Q P, et al.Impact of drug conjugation and loading on target antigen binding and cytotoxicity in cysteine antibody-drug conjugates [J].Mol Pharm, 2021, 18(3): 889-897., articleTitle=null, refAbstract=null), Reference(id=1322624451586412826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Deslignière E, Diemer H, Erb S, et al.A combination of native LC-MS approaches for the comprehensive characterization of the antibody-drug conjugate trastuzumab deruxtecan [J].Front Biosci (Landmark Ed), 2022, 27(10):290., articleTitle=null, refAbstract=null), Reference(id=1322624453264134427, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Szijj P A, Bahou C, Chudasama V.Addressing the retro-Michael instability of maleimide bioconjugates [J].Drug Discovery Today: Technol, 2018, 30: 27-34., articleTitle=null, refAbstract=null), Reference(id=1322624453368992028, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Nittoli T, Kelly M P, Delfino F, et al.Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids[J].Bioorg Med Chem, 2018, 26(9): 2271-2279., articleTitle=null, refAbstract=null), Reference(id=1322624453444489501, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Kerstin W S, Leanne L, Jenny L, et al.Abstract 219: the potential benefit of lower drug-antibody ratio(DAR) on antibody-maytansinoid conjugate in vivo efficacy [J].Cancer Res, 2019, 79(13_Supplement): 219., articleTitle=null, refAbstract=null), Reference(id=1322624453549347102, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Gu T Q, Xiao Y L, Shao Z M.Intratumor heterogeneity in breast cancer: tracing its origins and translating findings into clinical practice [J].Precis Med Eng, 2024, 1: 100006., articleTitle=null, refAbstract=null), Reference(id=1322624453620650271, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Yamazaki C M, Yamaguchi A, Anami Y, et al.Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance [J].Nat Commun, 2021,12: 3528., articleTitle=null, refAbstract=null), Reference(id=1322624453708730656, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Nguyen T D, Bordeau B M, Balthasar J P.Mechanisms of ADC toxicity and strategies to increase ADC tolerability [J]., articleTitle=null, refAbstract=null), Reference(id=1322624453813588257, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=de Bever L, Popal S, van Schaik J, et al.Generation of DAR1 antibody-drug conjugates for ultrapotent payloads using tailored GlycoConnect technology[J].Bioconjugate Chem,2023, 34(3): 538-548., articleTitle=null, refAbstract=null), Reference(id=1322624453910057250, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Clardy S M, Uttard A, Du B, et al.Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios [J].Mol Cancer Ther, 2024, 23(1): 84-91., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2026.09.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2026.09.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2026.09.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2026.09.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1788969600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
抗体偶联药物中药物-抗体比的检测方法以及均一性的设计策略
樊梦妮 , 张婷婷 , 秦国宏 *
中国医药工业杂志 | 专论与综述 2026,57(9): 1030-1038
收起
收藏切换
中国医药工业杂志 |专论与综述 2026 , 57 (9) : 1030 -1038
抗体偶联药物中药物-抗体比的检测方法以及均一性的设计策略
全屏
[Author(id=1322624445152350417, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322624445236236499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445152350417, language=EN, stringName=Mengni FAN, firstName=Mengni, middleName=null, lastName=FAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445303345364, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445152350417, language=CN, stringName=樊梦妮, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio={"content":"

樊梦妮,工程师,硕士,从事新药相关的质量研究。

"}, bioImg=null, bioContent=

樊梦妮,工程师,硕士,从事新药相关的质量研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])]), Author(id=1322624445383037142, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322624445479506136, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445383037142, language=EN, stringName=Tingting ZHANG, firstName=Tingting, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445546615001, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445383037142, language=CN, stringName=张婷婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])]), Author(id=1322624445630501083, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322624445714387165, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445630501083, language=EN, stringName=Guohong QIN, firstName=Guohong, middleName=null, lastName=QIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322624445781496030, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, authorId=1322624445630501083, language=CN, stringName=秦国宏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322624445047492813, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, xref=null, ext=[AuthorCompanyExt(id=1322624445060075726, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046), AuthorCompanyExt(id=1322624445072658639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1322624442665128136, companyId=1322624445047492813, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046)])])]
樊梦妮, 张婷婷, 秦国宏*
作者信息
  • 南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046
通讯作者:
秦国宏,副研究员,博士,从事新药研发工作。
作者简介:

樊梦妮,工程师,硕士,从事新药相关的质量研究。

Detection Methods for the Drug-antibody Ratio in Antibody-drug Conjugates and Design Strategies for Homogeneity
Mengni FAN, Tingting ZHANG, Guohong QIN*
Affiliations
  • Fanghua Pharmaceutical Research Institute, Nanjing Chia Tai Tianqing Pharmaceutical Company, Nanjing 210046
出版时间: 2026-09-10 doi: 10.16522/j.cnki.cjph.2026.09.002
文章导航
收藏切换

药物-抗体比(DAR)是抗体偶联药物的核心质量属性,直接影响其疗效、安全性和药代动力学特性。文章系统总结了DAR的检测方法及均一性ADC的优化策略。现有检测技术包括疏水作用色谱、反相高效液相色谱、质谱法、紫外-可见光谱法及新兴的多维液相联用技术等。在均一性优化方面,工程化定点偶联(如THIOMAB、酶催化偶联等)可实现DAR的精确控制;连接子的亲水性修饰与有效载荷结构的优化,均有助于提高载药量并维持抗体稳定性。确定最佳DAR时,需综合考虑靶标表达、肿瘤异质性及有效载荷性质等因素。该文可为ADC的工艺开发与质量控制提供参考。

抗体偶联药物  /  药物-抗体比  /  抗肿瘤药  /  检测方法  /  偶联策略  /  均一性  /  研究进展

The drug-to-antibody ratio(DAR) is a critical quality attribute of antibody-drug conjugates(ADCs),directly affecting their efficacy, safety, and pharmacokinetic properties. This review systematically summarizes the analytical methods for DAR determination and optimization strategies for homogeneous ADCs. Current detection technologies include hydrophobic interaction chromatography, reversed-phase high-performance liquid chromatography, mass spectrometry,ultraviolet-visible spectroscopy, and emerging multi-dimensional liquid chromatography hyphenated techniques. In terms of homogeneity optimization, engineered site-specific conjugation approaches(e.g., THIOMAB, enzymatic conjugation)enable precise control of DAR. Hydrophilic modification of linkers and optimization of payload structure help improve drug loading while maintaining antibody stability. The optimal DAR should be determined by comprehensively considering target expression levels, tumor heterogeneity, and payload properties. This review provides references for ADC process development and quality control.

antibody-drug conjugate  /  drug-to-antibody ratio  /  antineoplastics  /  detection method  /  conjugation strategy  /  homogeneity  /  research progress
樊梦妮, 张婷婷, 秦国宏. 抗体偶联药物中药物-抗体比的检测方法以及均一性的设计策略. 中国医药工业杂志, 2026 , 57 (9) : 1030 -1038 . DOI: 10.16522/j.cnki.cjph.2026.09.002
Mengni FAN, Tingting ZHANG, Guohong QIN. Detection Methods for the Drug-antibody Ratio in Antibody-drug Conjugates and Design Strategies for Homogeneity[J]. Chinese Journal of Pharmaceuticals, 2026 , 57 (9) : 1030 -1038 . DOI: 10.16522/j.cnki.cjph.2026.09.002

参考文献 引证文献
排序方式:
[1]
Ducry L, Stump B.Antibody—drug conjugates: LINking cytotoxic payloads to monoclonal antibodies [J].Bioconjug Chem, 2010, 21(1): 5-13.
[2]
Kvirkvelia N, Chikadze N, Makinde J, et al.Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine [J].Clin Exp Immunol, 2018, 193(1): 73-83.
[3]
Dan N, Setua S, Kashyap V K, et al.Antibody-drug conjugates for cancer therapy: chemistry to clinical implications [J].Pharmaceuticals, 2018, 11(2): 32.
[4]
郭立红, 王金朋, 翟立海, 等.抗体偶联药物和小分子偶联药物的研究进展[J].中国医药工业杂志, 2019, 50(8):842-851.
[5]
Casi G, Neri D.Antibody-drug conjugates: basic concepts,examples and future perspectives [J].J Control Release,2012, 161(2): 422-428.
[6]
Sassoon I, Blanc V.Antibody-drug conjugate(ADC) clinical pipeline: a review [J].Methods Mol Biol, 2013, 1045: 1-27.
[7]
Ducry L.Antibody-drug conjugates [M].Berlin/Heidelberg: Springer Science, 2013.
[8]
Hinrichs M J M, Dixit R.Antibody drug conjugates:nonclinical safety considerations [J].AAPS J, 2015, 17:1055-1064.
[9]
Hamilton G S.Antibody-drug conjugates for cancer therapy:the technological and regulatory challenges of developing drug-biologic hybrids [J].Biologicals, 2015, 43(5): 318-332.
[10]
Lambert J M.Antibody-drug conjugates(ADC): magic bullets at last! [J].Mol Pharm, 2015, 12(6): 1701-1702.
[11]
Diamantis N, Banerji U.Antibody-drug conjugates: an emerging class of cancer treatment [J].Br J Cancer, 2016,114: 362-367.
[12]
Mahmood I.Clinical pharmacology of antibody-drug conjugates [J].Antibodies, 2021, 10(2): 20.
[13]
Hussain A F, Grimm A, Sheng W J, et al.Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches [J].Pharmaceuticals, 2021, 14(4):343.
[14]
Guo J X, Kumar S, Chipley M, et al.Characterization and higher-order structure assessment of an interchain cysteine-based ADC: impact of drug loading and distribution on the mechanism of aggregation [J].Bioconjug Chem, 2016,27(3): 604-615.
[15]
Aoyama M, Tada M, Yokoo H, et al.Linker and conjugation site synergy in antibody-drug conjugates: impacts on biological activity [J].Bioconjug Chem, 2024, 35(10): 1568-1576.
[16]
Metrangolo V, Engelholm L H.Antibody-drug conjugates:the dynamic evolution from conventional to next-generation constructs [J].Cancers, 2024, 16(2): 447.
[17]
Matsuda Y, Leung M, Okuzumi T, et al.A purification strategy utilizing hydrophobic interaction chromatography to obtain homogeneous species from a site-specific antibody drug conjugate produced by AJICAP™ first generation [J].Antibodies, 2020, 9(2): 16.
[18]
Haverick M, Mengisen S, Shameem M, et al.Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications [J].mAbs, 2014, 6(4): 852-858.
[19]
Matsuda Y, Robles V, Malinao M C, et al.Comparison of analytical methods for antibody-drug conjugates produced by chemical site-specific conjugation: first-generation AJICAP[J].Anal Chem, 2019, 91(20): 12724-12732.
[20]
Cordova J C, Sun S, Bos J, et al.Development of a single-step antibody-drug conjugate purification process with membrane chromatography [J].J Clin Med, 2021, 10(3):552.
[21]
XU Y R, JISNG G F, TRAN C, et al.RP-HPLC DAR characterization of site-specific antibody drug conjugates produced in a cell-free expression system [J].Org Process Res Dev, 2016, 20(6): 1034-1043.
[22]
Chen T H, Yang Y, Zhang Z R, et al.Native reversed-phase liquid chromatography: a technique for LCMS of intact antibody-drug conjugates [J].Anal Chem, 2019, 91(4):2805-2812.
[23]
Srikanth K, David P, Sayumi Y, et al.Universal affinity capture liquid chromatography-mass spectrometry assay for evaluation of biotransformation of site-specific antibody drug conjugates in preclinical studies [J].Anal Chem, 2020,92(2): 2065-2073.
[24]
Chen L X, Wang L, Shion H, et al.In-depth structural characterization of Kadcyla®(ado-trastuzumab emtansine) and its biosimilar candidate [J].mAbs, 2016, 8(7): 1210-1223.
[25]
Wang T D, Huang Z A, Zhou M Y, et al.Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates [J].J Pharm Biomed Anal, 2024, 243:116098.
[26]
Källsten M, Hartmann R, Artemenko K, et al.Qualitative analysis of antibody-drug conjugates(ADCs): an experimental comparison of analytical techniques of cysteine-linked ADCs[J].Analyst, 2018, 143(22): 5487-5496.
[27]
Jones J, Pack L, Hunter J H, et al.Native size-exclusion chromatography-mass spectrometry: suitability for antibody-drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels [J].mAbs,2019, 12(1): 1682895.
[28]
Leblanc Y, Faid V, Lauber M A, et al.A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry [J].J Chromatogr B,2019, 1133: 121814.
[29]
Matsuda Y, Kliman M, Mendeisohn B A.Application of native ion exchange mass spectrometry to intact and subunit analysis of site-specific antibody-drug conjugates produced by AJICAP first generation technology [J].J Am Soc Mass Spectrom, 2020, 31(8): 1706-1712.
[30]
Zong H F, Li X, Han L, et al.A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer [J].Acta Pharmacol Sin, 2024, 45(8): 1727-1739.
[31]
Andris S, Rüdt M, Rogalla J, et al.Monitoring of antibody-drug conjugation reactions with UV/Vis spectroscopy [J].J Biotechnol, 2018, 288: 15-22.
[32]
Botzanowski T, Erb S, Hernandez-Alba O, et al.Insights from native mass spectrometry approaches for top- and middle-level characterization of site-specific antibody-drug conjugates [J].mAbs, 2017, 9(5): 801-811.
[33]
Kempen T, Cadang L, Fan Y C, et al.Online native hydrophobic interaction chromatography-mass spectrometry of antibody-drug conjugates [J].mAbs, 2024, 17(1): 2446304.
[34]
Alicja M, Świderska K W, Otlewski J.Current methods for the synthesis of homogeneous antibody-drug conjugates [J].Biotechnol Adv, 2015, 33(6): 775-784.
[35]
Gao W L, Zhang J X, Xiang J, et al.Recent advances in site specific conjugations of antibody drug conjugates(ADC) [J].Curr Cancer Drug Targets, 2016, 16(6): 469-479.
[36]
Sun X X, Ponte J F, Yoder N C, et al.Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy,and tolerability of antibody-maytansinoid conjugates [J].Bioconjug Chem, 2017, 28(5): 1371-1381.
[37]
D’Atri V, Peli R, Clarke A, et al.Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates? [J].J Chromatogr A,2019, 1586: 149-153.
[38]
Panowski S, Bhakta S, Raab H, et al.Site-specific antibody drug conjugates for cancer therapy [J].mAbs, 2014, 6(1):34-45.
[39]
Ou C, Li C, Zhang R S, et al.One-pot conversion of free sialoglycans to functionalized glycan oxazolines and efficient synthesis of homogeneous antibody-drug conjugates through site-specific chemoenzymatic glycan remodeling [J].Bioconjug Chem, 2021, 32(8): 1888-1897.
[40]
Farràs M, Miret J, Camps M, et al.Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly [J].mAbs,2020, 12(1): 1702262.
[41]
Dannheim F M, Stephen W, Orozco C T, et al.All-in-one disulfide bridging enables the generation of antibody conjugates with modular cargo loading [J].Chem Sci, 2022,13(30): 8781-8790.
[42]
Wang Z J, Li H X, Gou L T, et al.Antibody-drug conjugates:recent advances in payloads [J].Acta Pharm Sin B, 2023,13(10): 4025-4059.
[43]
Goldenberg D M, Cardillo T M, Govindan S V, et al.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan(IMMU-132), an antibody-drug conjugate(ADC)[J].Oncotarget, 2015, 6(26): 22496-22512.
[44]
马骏威, 刘永辉, 任连杰.抗体偶联药物的小分子部分药学研究考虑 [J].中国医药工业杂志, 2025, 56(11): 1464-1470.
[45]
Nadkarni D V, Lee J, Jiang Q P, et al.Impact of drug conjugation and loading on target antigen binding and cytotoxicity in cysteine antibody-drug conjugates [J].Mol Pharm, 2021, 18(3): 889-897.
[46]
Deslignière E, Diemer H, Erb S, et al.A combination of native LC-MS approaches for the comprehensive characterization of the antibody-drug conjugate trastuzumab deruxtecan [J].Front Biosci (Landmark Ed), 2022, 27(10):290.
[47]
Szijj P A, Bahou C, Chudasama V.Addressing the retro-Michael instability of maleimide bioconjugates [J].Drug Discovery Today: Technol, 2018, 30: 27-34.
[48]
Nittoli T, Kelly M P, Delfino F, et al.Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids[J].Bioorg Med Chem, 2018, 26(9): 2271-2279.
[49]
Kerstin W S, Leanne L, Jenny L, et al.Abstract 219: the potential benefit of lower drug-antibody ratio(DAR) on antibody-maytansinoid conjugate in vivo efficacy [J].Cancer Res, 2019, 79(13_Supplement): 219.
[50]
Gu T Q, Xiao Y L, Shao Z M.Intratumor heterogeneity in breast cancer: tracing its origins and translating findings into clinical practice [J].Precis Med Eng, 2024, 1: 100006.
[51]
Yamazaki C M, Yamaguchi A, Anami Y, et al.Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance [J].Nat Commun, 2021,12: 3528.
[52]
Nguyen T D, Bordeau B M, Balthasar J P.Mechanisms of ADC toxicity and strategies to increase ADC tolerability [J].
[53]
de Bever L, Popal S, van Schaik J, et al.Generation of DAR1 antibody-drug conjugates for ultrapotent payloads using tailored GlycoConnect technology[J].Bioconjugate Chem,2023, 34(3): 538-548.
[54]
Clardy S M, Uttard A, Du B, et al.Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of drug to antibody ratios [J].Mol Cancer Ther, 2024, 23(1): 84-91.
2026年第57卷第9期
274
78
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2026.09.002
  • 接收时间:2025-08-12
  • 首发时间:2026-10-29
  • 出版时间:2026-09-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-08-12
基金
作者信息
    南京正大天晴制药有限公司,芳华药物研究院,江苏 南京 210046

通讯作者:

秦国宏,副研究员,博士,从事新药研发工作。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2026.09.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏